YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2Y641mut germinal center-derived lymphoma
A significant proportion of diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) cases harbor a gain-of-function, heterozygous somatic mutation of the methyltransferase gene EZH2. While this factor is known to cooperate with the proto-oncogene MYC during malignant B cell development, t...
Saved in:
Main Authors: | Aránzazu Chamorro-Jorganes, Núria Profitós-Pelejà, Clara Recasens-Zorzo, Juan G Valero, Diana Reyes-Garau, Laura Magnano, Ray Butler, Antonio Postigo, Patricia Pérez-Galán, Marcelo Lima Ribeiro, Gaël Roué |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-03-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558625000107 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molecular cloning of EZH2 oncogene in chronic myeloid leukemia and therapeutic prospects
by: Juliana Costa Gaspar, et al.
Published: (2015-07-01) -
Targeting EZH1/2: tackling epigenetic resistance advances cancer therapy
by: Ram Abou Zaki, et al.
Published: (2025-01-01) -
Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer
by: Jilong Hu, et al.
Published: (2021-01-01) -
Safety profile of EZH2 inhibitors for cancer: a systematic review and meta-analysis
by: Zhou Zhao, et al.
Published: (2025-01-01) -
EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction
by: Rui Liu, et al.
Published: (2025-01-01)